CTLA4 and neoplasm: In this approach, one CAR receptor‐targeted at tumor antigen that initiates the kill switch upon encounter with tumor cells and another inhibitory CAR molecule that expresses the inhibitory signal (such as CTLA‐4 or PD‐1) when in contact with antigens on normal tissue should be engineered onto T cells.136